Milrinone, a derivative of amrinone, has nearly 20 times the inotropic potency of the parent compound and does not cause fever or thrombocytopenia in normal volunteers or in animals sensitive to amrinone. In 20 patients with severe congestive heart failure, intravenous milrinone resulted in significant decreases in left ventricular end-diastolic pressure (from 27 +/- 2 to 18 +/- 2 mm Hg), pulmonary wedge pressure, right atrial pressure, and systemic vascular resistance, as well as a slight reduction in mean arterial pressure. Significant increases occurred in cardiac index (from 1.9 +/- 0.1 to 2.9 +/- 0.2 liters per minute per square meter) and the peak positive first derivative of left ventricular pressure, with a slight increase in heart rate. Hemodynamic improvement was sustained during a 24-hour continuous infusion. Nineteen of the 20 patients subsequently received oral milrinone (29 +/- 2 mg per day) for up to 11 months (mean, 6.0 +/- 0.8), with sustained improvement in symptoms of heart failure. In 10 patients receiving long-term oral milrinone (greater than or equal to 6 months) radionuclide ventriculography showed continued responsiveness, with a 27 per cent increase in left ventricular ejection fraction after 7.5 mg of the drug. Four patients died after a mean of 4.8 months of therapy, and three patients with severe underlying coronary-artery disease and angina pectoris required additional antianginal therapy. No patient had fever, thrombocytopenia, gastrointestinal intolerance, or aggravation of ventricular ectopy. We conclude that milrinone shows promise for the longterm treatment of congestive heart failure.
This article has been cited by other articles:
Lamarche, Y., Perrault, L. P., Maltais, S., Tetreault, K., Lambert, J., Denault, A. Y.
(2007). Preliminary experience with inhaled milrinone in cardiac surgery. Eur. J. Cardiothorac. Surg.
31: 1081-1087
[Abstract][Full Text]
Yan, C., Miller, C. L., Abe, J.-i.
(2007). Regulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart. Circ. Res.
100: 489-501
[Abstract][Full Text]
Denault, A. Y., Lamarche, Y., Couture, P., Haddad, F., Lambert, J., Tardif, J.-C., Perrault, L. P.
(2006). Inhaled milrinone: a new alternative in cardiac surgery?. SEMIN CARDIOTHORAC VASC ANESTH
10: 346-360
[Abstract]
Granger, C. B., McMurray, J. J.V.
(2006). Using Measures of Disease Progression to Determine Therapeutic Effect: A Sirens' Song. J Am Coll Cardiol
48: 434-437
[Abstract][Full Text]
Wei, W., Yang, C.-Q., Furnary, A., He, G.-W.
(2005). Greater vasopressin-induced vasoconstriction and inferior effects of nitrovasodilators and milrinone in the radial artery than in the internal thoracic artery. J. Thorac. Cardiovasc. Surg.
129: 33-40
[Abstract][Full Text]
Movsesian, M. A
(2004). Altered cAMP-mediated signalling and its role in the pathogenesis of dilated cardiomyopathy. Cardiovasc Res
62: 450-459
[Abstract][Full Text]
Salenger, R., Gammie, J. S., Vander Salm, T. J.
(2003). Postoperative Care of Cardiac Surgical Patients. Card Surg Adult
2: 439-469
[Full Text]
Levy, J. H., Bailey, J. M., Deeb, G. M.
(2002). Intravenous milrinone in cardiac surgery. Ann. Thorac. Surg.
73: 325-330
[Abstract][Full Text]
Kikura, M., Sato, S.
(2002). The Efficacy of Preemptive Milrinone or Amrinone Therapy in Patients Undergoing Coronary Artery Bypass Grafting. Anesth. Analg.
94: 22-30
[Abstract][Full Text]
Janelle, G. M., Urdaneta, F., Blas, M. L., Shryock, J., Tang, Y.-S., Martin, T. D., Lobato, E. B.
(2001). Inhibition of Phosphodiesterase Type III Before Aortic Cross-Clamping Preserves Intramyocardial Cyclic Adenosine Monophosphate During Cardiopulmonary Bypass. Anesth. Analg.
92: 1377-1383
[Abstract][Full Text]
Movsesian, M. A.
(1999). Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate. J Am Coll Cardiol
34: 318-324
[Abstract][Full Text]
Lin, H.-Y., Yen, P. M., Davis, F. B., Davis, P. J.
(1997). Protein synthesis-dependent potentiation by thyroxine of antiviral activity of interferon-gamma. Am. J. Physiol. Cell Physiol.
273: C1225-C1232
[Abstract][Full Text]
Liu, J. J., Doolan, L. A., Xie, B., Chen, J. R., Buxton, B. F.
(1997). DIRECT VASODILATOR EFFECT OF MILRINONE, AN INOTROPIC DRUG, ON ARTERIAL CORONARY BYPASS GRAFTS. J. Thorac. Cardiovasc. Surg.
113: 108-113
[Abstract][Full Text]
Feldman, M. D., Pak, P. H., Wu, C. C., Haber, H. L., Heesch, C. M., Bergin, J. D., Powers, E. R., Cowart, T. D., Johnson, W., Feldman, A. M., Kass, D. A.
(1996). Acute Cardiovascular Effects of OPC-18790 in Patients With Congestive Heart Failure : Time- and Dose-Dependence Analysis Based on Pressure-Volume Relations. Circulation
93: 474-483
[Abstract][Full Text]
Feldman, A. M.
(1992). Can We Alter Survival in Patients With Congestive Heart Failure?. JAMA
267: 1956-1961
[Abstract]
Goldberg, E., Berdoff, R., Spivack, G., Haimowitz, A., Tay, S.
(1987). Evaluation of the Vasodilator vs Inotropic Effect of Milrinone Using an Animal Model of Left Ventricular Failure: Reversal of Disopyramide Depression of the Myocardium with Milrinone. ANGIOLOGY
38: 657-662
[Abstract]
Goldenberg, I. F., Cohn, J. N.
(1987). New Inotropic Drugs for Heart Failure. JAMA
258: 493-496
[Abstract]
Previous
